Giant pelvic angiomyofibroblastoma: case report and literature review
© Qiu et al.; licensee BioMed Central Ltd. 2014
Received: 22 March 2014
Accepted: 11 May 2014
Published: 3 June 2014
Angiomyofibroblastoma (AMF) is a rare, benign, soft-tissue tumor, which predominantly occurs in the vulvovaginal region of middle-aged women. It is clinically important to distinguish an AMF from other stromal cell lesions. Here, we report the case of a 32-year-old woman with a rare, giant pelvic AMF, which showed a benign clinical course. The tumor was located in the cul-de-sac of Douglas. It was well demarcated, hypocellular, edematous and composed of spindle-shaped and oval stromal cells aggregating around thin-walled blood vessels. The tumor cells had abundant eosinophilic cytoplasm, and expressed estrogen receptors, progesterone receptors and desmin. Mitotic figures were absent. It is important to distinguish AMFs from aggressive angiomyxomas because both occur at similar sites but show different clinical behaviors. Most AMFs and aggressive angiomyxomas have the same immunohistochemical phenotype. The well-circumscribed borders of AMF are the most important characteristic that distinguish it from aggressive angiomyxomas. AMFs rarely recur after complete surgical excision.
The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/5510813471244189.
KeywordsAngiomyofibroblastoma (AMF) Aggressive angiomyxoma (AAM) Pelvis
Angiomyofibroblastoma (AMF) is a rare soft-tissue neoplasm that most frequently affects the lower genital tracts of young to middle-aged women. This tumor belongs to the group of genital mesenchymal tumors . These tumors commonly involve the vulva, perineum, vagina, uterine cervix [2–4] and the inguinoscrotal regions of men , but only rarely occur in the pelvis or retroperitoneum. Rare recurrences of AMF after excision have been reported in the literature .Here, we report a case of a giant AMF in an uncommon location, namely, the pelvic region. We also emphasize the difficulty in making an accurate preoperative diagnosis. The differential diagnosis for such a tumor includes an aggressive angiomyxoma (AAM), which unlike AMF, does not have well-defined margins.
AMF is a rare, benign, soft-tissue tumor that shows myofibroblastic differentiation and represents neoplastic proliferation of stromal cells. AMF was first described by Fletcher et al. in 1992 . AMF is composed of myofibroblastic cells and prominent thin-walled blood vessels within a fibromxyoid stroma. Its cause and pathogenesis are unknown at present. Since AMF is rare, no statistical data are available about its incidence in the general population. In most reports, AMF has occurred in women aged between 20 and 50 years, i.e., during the reproductive years [1, 2]. There are very rare reports of AMF occurring in male patients [5, 7]. Most cases of AMF are benign, and only one case with sarcomatous transformation has ever been reported . A rare lipomatous variant of AMF with local invasion has also been reported [9, 10].
Clinical features of female pelvic AMF
Several reports have analyzed the imaging features of AMFs. On perineal ultrasonography, AMFs appear as a soft-tissue mass with inhomogeneous mixed echogenicity, which corresponds to the cellular inhomogeneity found on histopathological examination. Therefore, the ultrasonographic characteristics of AMFs may help to differentiate them from other mesenchymal neoplasms . On CT imaging, AMFs most likely show moderate-to-strong enhancement, which may reflect the prominent vascularity of these tumors . There have been three cases of AMF which showed well-defined margins and heterogeneous or homogeneous intermediate signal intensity on CT. In the current case, the small, hypoechoic area inside the mass observed on ultrasound examination may be attributable to the flesh-like structures seen on gross examination.
IHC showed that the tumor expressed estrogen and progesterone receptors, which suggests that it might have originated as a neoplastic proliferation of hormonally responsive mesenchymal cells.
As AMF has a benign clinical course, it should be differentiated from other tumor-like lesions of the vulvovaginal region including Bartholin cysts,benign lipoma,fibroepithelial stromal polyps and cellular angiofibromas[1–4, 9, 10].
In the present case, AMF could be readily distinguished from Bartholin cysts and fibroepithelial stromal polyps according to histopathological and immunohistochemical findings. The distinction between AMF and cellular angiofibroma, both of which have a characteristic vascular network and spindle cell component, is relatively subtle. However, cellular angiofibroma is characterized by the presence of spindle cell lipomas and thick-walled vessels. Meanwhile, cellular angiofibromas lack ER and PR .
Aggressive angiomyxoma(AAM) is most likely to be confused with AMF because it shares many features with AMF including age at presentation, location, clinical manifestations and pathological entities. However, AAM presents as a malignant, locally infiltrative, non-metastasizing stromal neoplasm with a strong tendency to recur. On microscopic examination, AMFs generally show much higher cellularity, more numerous blood vessels and more frequent plump or short spindle-shaped cells; in contrast, AAM cells are sparsely and diffusely distributed, without the characteristics of alternating density and aggregation around small blood vessels. AAMs show more distinctive myxoid degeneration than AMFs [1, 17]. AMFs are characterized by the expression of vimentin, desmin and CD34, suggesting an undifferentiated mesenchymal tumor with preferential myofibroblastic differentiation. Desmin expression was previously thought to be specific for AMFs, but positive expression of desmin has been found in some cases of AAMs. Most AAMs are also positive for estrogen and progesterone receptors. Hence, desmin, estrogen receptor and progesterone receptor are no longer considered reliable markers for distinguishing AAMs from AMFs . After surgical treatment, 30% of AAMs have been found to relapse within 2 years . Since the morphology and IHC markers of AMF are similar to those of AAM, differentiation between these two tumors is largely based on the appearance of the tumor margins (AMFs are well demarcated).
As AMF is a commom perineum-site-specific stromal tumour, a benign neoplasm of dendritic fibromyxolipoma (DFML) in rare sites such as perineum regions should be differentiated from AMF. Zhang XJ et al.  recently reported the case of a woman of similar age to our current case with a slow-growing, painless, subcutaneous tumor in the right inguinal and perineal regions which was diagnosed as DFML lately. Histologically, DFML is mainly composed of a proliferation of small spindle or stellate cells that are variably admixed with mature adipose tissue embedded within an abundant myxoid and collagenized stroma. Immunohistochemically, the spindle and stellate cells are strongly positive for vimentin, CD34, and bcl-2 antibodies but not for smooth muscle actin and desmin. The above-mentioned histopathological and immunohistochemical findings can easily distinguish AMF from DFML.
The pathological differential diagnosis should also include inflammatory myofibroblastic (IMT) which has myofibroblastic differentiation . These are rare benign lesions that are predominately located in the lung. Microscopic examination reveals a proliferation of regular myofibroblastic spindle cells arranged within a fibrous, myxoid or calcified stroma, associated with an inflammatory component of lymphocytes and plasmacytes but without blood vessels . Immunohistochemical studies show reactivity for vimentin, smooth muscle actin and ALK.
The treatment of choice for AMF is simple total excision, which is usually curative, and there are almost no incidences of recurrences or metastasis after complete excision, which confirms the benign nature of AMF . AMF shows no propensity for infiltrative growth.
Pelvic AMF is extremely rare but is benign. Its preoperative diagnosis and differentiation from other soft-tissue tumors are challenging. The combination of radiological data, and histological and IHC findings can confirm the diagnosis.
Written informed consent was obtained from the patient to approve the publication of this Case Report and any accompanying images.
- Fletcher CD, Tsang WY, Fisher C, Lee KC, Chan JK: Angiomyofibroblastoma of the vulva. A benign neoplasm distinct from aggressive angiomyxoma. Am J Surg Pathol. 1992, 16: 373-382. 10.1097/00000478-199204000-00006.PubMedView ArticleGoogle Scholar
- Babala P, Biro C, Klacko M, Miklos P, Ondrus D: Angiomyofibroblastoma of the cervix uteri: a case report. Klin Onkol. 2011, 24: 133-136.PubMedGoogle Scholar
- Mortele KJ, Lauwers GJ, Mergo PJ, Ros PR: Perineal angiomyofibroblastoma: CT and MR findings with pathologic correlation. J Comput Assist Tomogr. 1999, 23: 687-689. 10.1097/00004728-199909000-00007.PubMedView ArticleGoogle Scholar
- Naheed S, Upadhyay K, Pradeep K: Angiomyofibroblastoma of the vulva. J Obstet Gynaecol. 2011, 31: 554-555. 10.3109/01443615.2011.581314.PubMedView ArticleGoogle Scholar
- Lee SH, Yang JW, Do JM, Seo DH, Jung JH, Chung KH, Lee JS, Hyun JS: Angiomyofibroblastoma-like tumor of the scrotum. Korean J Urol. 2010, 51: 365-367. 10.4111/kju.2010.51.5.365.PubMedPubMed CentralView ArticleGoogle Scholar
- Saleh MM, Yassin AH, Zaklama MS: Recurrent angiomyofibroblastoma of the vagina: a case report. Eur J Gynaecol Oncol. 2007, 28: 324-PubMedGoogle Scholar
- Ding G, Yu Y, Jin M, Xu J, Zhang Z: Angiomyofibroblastoma-like tumor of the scrotum: a case report and literature review. Oncol Lett. 2014, 7: 435-438.PubMedPubMed CentralGoogle Scholar
- Nielsen GP, Young RH, Dickersin GR, Rosenberg AE: Angiomyofibroblastoma of the vulva with sarcomatous transformation (“angiomyofibrosarcoma”). Am J Surg Pathol. 1997, 21: 1104-1108. 10.1097/00000478-199709000-00016.PubMedView ArticleGoogle Scholar
- Laskin WB, Fetsch JF, Tavassoli FA: Angiomyofibroblastoma of the female genital tract: analysis of 17 cases including a lipomatous variant. Hum Pathol. 1997, 28: 1046-1055. 10.1016/S0046-8177(97)90058-7.PubMedView ArticleGoogle Scholar
- Vora S, Gaba ND, Stamatakos MD: Lipomatous angiomyofibroblastoma: a case report of a unique vulvar mass. J Reprod Med. 2011, 56: 347-350.PubMedGoogle Scholar
- Kitamura H, Miyao N, Sato Y, Matsukawa M, Tsukamoto T, Sato T: Angiomyofibroblastoma of the female urethra. Int J Urol. 1999, 6: 268-270. 10.1046/j.1442-2042.1999.00059.x.PubMedView ArticleGoogle Scholar
- Quintero C, Sasken H, Houck KL, Hernandez E: Angiomyofibroblastoma of the retroperitoneum: a case report. J Reprod Med. 2007, 52: 741-744.PubMedGoogle Scholar
- Menendez SP, Villarejo CP, Padilla VD, Munoz AV, Gonzalez LL, Martin FJ: Angiomyofibroblastoma of the right ischiorectal fosa. Cir Cir. 2010, 78: 448-450.Google Scholar
- Lim KJ, Moon JH, Yoon DY, Cha JH, Lee IJ, Min SJ: Angiomyofibroblastoma arising from the posterior perivesical space: a case report with MR findings. Korean J Radiol. 2008, 9: 382-385. 10.3348/kjr.2008.9.4.382.PubMedPubMed CentralView ArticleGoogle Scholar
- Kobayashi T, Suzuki K, Arai T, Sugimura H: Angiomyofibroblastoma arising from the fallopian tube. Obstet Gynecol. 1999, 94: 833-834. 10.1016/S0029-7844(99)00362-2.PubMedView ArticleGoogle Scholar
- Kim SW, Lee JH, Han JK, Jeon S: Angiomyofibroblastoma of the vulva: sonographic and computed tomographic findings with pathologic correlation. J Ultrasound Med. 2009, 28: 1417-1420.PubMedGoogle Scholar
- Steeper TA, Rosai J: Aggressive angiomyxoma of the female pelvis and perineum. Report of nine cases of a distinctive type of gynecologic soft-tissue neoplasm. Am J Surg Pathol. 1983, 7: 463-475. 10.1097/00000478-198307000-00009.PubMedView ArticleGoogle Scholar
- Zhang XJ, Zhou S, Nie K, Chen DF, Kui GJ, Zhang XH: Dendritic fibromyxolipoma in the right inguinal and perineum regions: a case report and review of the literature. Diagn Pathol. 2013, 8: 157-163. 10.1186/1746-1596-8-157.PubMedPubMed CentralView ArticleGoogle Scholar
- Nawal H, Laila C, Mohammed R, Meryem B, Sara B, Youssef B, Siham T, Mustapha H, Afaf A: A rare tumor of the lung: inflammatory myofibroblastic tumor. Diagn Pathol. 2012, 7: 83-86. 10.1186/1746-1596-7-83.View ArticleGoogle Scholar
- Stewart C: Angiomyofibroblastoma of the vagina. Pathology. 2009, 41: 199-200. 10.1080/00313020802579383.PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.